FrancophonIA/ELRC3.0 huggingface dataset:
English: The safety of the vaccine was studied in laboratory safety studies carried out with an overdose of Bovilis BTV8 in young lambs and calves and in pregnant ewes and cows.
Estonian: Vaktsiini ohutust uuriti laboratoorsetes ohutusuuringutes, milles manustati Bovilis BTV8 üleannus noortele talledele ja vasikatele ning tiinetele uttedele ja lehmadele.
English: When it is given to cattle and sheep, the animals' immune system recognises the virus as ‘foreign' and produce antibodies against it.
Estonian: Kui seda manustatakse veistele ja lammastele, peab immuunsüsteem vaktsiinis sisalduvaid viiruseid võõraks ja tekitab nende vastu antikehi.
English: The CVMP concluded that the benefits of Bovilis BTV8 exceed the risks and recommended that Bovilis BTV8 be given a marketing authorisation.
Estonian: Veterinaarravimite komitee järeldas, et vaktsiini Bovilis BTV8 kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
English: Bovilis BTV8 contains bluetongue virus that has been inactivated so that it cannot cause the disease.
Estonian: Bovilis BTV8 sisaldab lammaste katarraalse palaviku viirust, mis on inaktiveeritud ega suuda seetõttu haigust tekitada.
English: This means that it was not possible at the time of the initial authorisation to obtain complete information about Bovilis BTV8.
Estonian: See tähendab, et vaktsiini Bovilis BTV8 kohta ei ole olnud esmase müügiloa andmisel võimalik saada täielikku teavet.
English: The first injection is given from one month of age in sheep and from six weeks of age in cattle.
Estonian: Esimene süst tehakse vähemalt ühe kuu vanustele lammastele ja vähemalt kuue nädala vanustele veistele.
English: Bovilis BTV8 is a vaccine.
Estonian: Bovilis BTV8 on vaktsiin.
English: The risk of bluetongue transmission to cattle following vaccination with Bovilis BTV8 was further investigated in two epidemiological models.
Estonian: Vaktsiini Bovilis BTV8 toimet lammaste katarraalse palaviku veistele ülekandumise riski suhtes hinnati kahe epidemioloogilise mudeli abil.
English: Bovilis BTV8 is a vaccine that contains an inactivated (killed) bluetongue serotype 8 virus as the active substance.
Estonian: Bovilis BTV8 on vaktsiin, mis sisaldab toimeainena lammaste katarraalse palaviku inaktiveeritud (hävitatud) viiruse 8. serotüüpi.
English: What is Bovilis BTV8?
Estonian: Mis on Bovilis BTV8?
English: Why has Bovilis BTV8 been approved?
Estonian: Miks Bovilis BTV8 heaks kiideti?
English: How does Bovilis BTV8 work?
Estonian: Kuidas Bovilis BTV8 toimib?
English: Inactivated adjuvanted vaccine against bluetongue virus serotype 8
Estonian: Lammaste katarraalse palaviku viiruse serotüübi 8 vastane vaktsiin (inaktiveeritud, adjuveeritud)
English: The efficacy of the vaccine in cattle and sheep was studied in a number of laboratory trials; in cattle from six weeks of age and in sheep from one month of age..
Estonian: Vaktsiini efektiivsust veistel ja lammastel uuriti mitmes laboriuuringus.
English: What is the risk associated with Bovilis BTV8?
Estonian: Mis riskid vaktsiiniga Bovilis BTV8 kaasnevad?
English: Bovilis BTV8 was shown to be safe for use in pregnant ewes and cattle.
Estonian: Uuringud näitasid, et vaktsiini Bovilis BTV8 manustamine tiinetele uttedele ja veistele on ohutu.
English: Bovilis BTV8 is used in cattle and sheep to protect them against bluetongue disease, an infection caused by the bluetongue virus which is transmitted by midges.
Estonian: Vaktsiini Bovilis BTV8 kasutatakse veiste ja lammaste kaitsmiseks lammaste katarraalse palaviku eest.
English: Other information about Bovilis BTV8:
Estonian: Muu teave vaktsiini Bovilis BTV8 kohta
English: The virus exists in several forms (serotypes) throughout the world; the type used in Bovilis BTV8 is serotype 8.
Estonian: Viirus esineb kogu maailmas mitme serotüübina.
English: How has Bovilis BTV8 been studied?
Estonian: Kuidas vaktsiini Bovilis BTV8 uuriti?
English: What is Bovilis BTV8 used for?
Estonian: Milleks vaktsiini Bovilis BTV8 kasutatakse?
English: What benefit has Bovilis BTV8 shown during the studies?
Estonian: Milles seisneb uuringute põhjal vaktsiini Bovilis BTV8 kasulikkus?
English: This summary was last updated in 02-2018.
Estonian: Kokkuvõtte viimane uuendus: 02-2018.
English: • do not grow normally because they do not have enough growth hormone;
Estonian: • kes ei kasva normaalselt, sest neil ei ole piisavalt kasvuhormooni;
English: The European Commission granted a marketing authorisation valid throughout the European Union for Omnitrope on 12 April 2006.
Estonian: Euroopa Komisjon andis Omnitrope müügiloa, mis kehtib kogu Euroopa Liidus, 12. aprillil 2006.
English: Children receiving Omnitrope and Genotropin grew at a similar rate of about 10.7 cm per year.
Estonian: Omnitropet ja Genotropini saanud lapsed kasvasid sarnase kiirusega, ligikaudu 10,7 cm aastas.
English: The diagnosis must be confirmed by genetic testing.
Estonian: Diagnoos peab olema kinnitatud asjakohase geenitestiga.
English: The full EPAR for Omnitrope can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Omnitrope kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: • have a genetic condition called Prader-Willi syndrome.
Estonian: • kellel on geenihäire Praderi-Willi sündroom.
English: These side effects are uncommon in children (may affect between 1 and 10 patients in 1,000).
Estonian: Lastel esinevad sellised kõrvalnähud aeg-ajalt (võivad esineda 1 kuni 10 patsiendil 1000st).
English: Omnitrope somatropin
Estonian: Omnitrope somatropiin
English: The deficiency can have started in adulthood or childhood, and needs to be confirmed by testing before treatment.
Estonian: Kasvuhormooni puudulikkus võib olla tekkinud täiskasvanu- või lapseeas ning see peab olema enne ravi testidega kinnitatud.
English: What is Omnitrope and what is it used for?
Estonian: Mis on Omnitrope ja milleks seda kasutatakse?
English: It must also not be used for promoting growth in children with closed epiphyses (when the large bones have finished growing).
Estonian: Samuti ei tohi seda kasutada kasvu soodustamiseks lastel, kellel on epifüüsid luustunud (toruluud on lõpetanud kasvamise).
English: It is important for growth during childhood and adolescence, and it also affects how the body handles proteins, fat and carbohydrates.
Estonian: See soodustab lapse- ja noorukieas kasvu ning mõjutab ka viisi, kuidas organism töötleb valke, rasvu ja süsivesikuid.
English: The dose may need to be adjusted over time, depending on change in body weight and response to treatment.
Estonian: Aja jooksul võib olla vaja annust kohandada, olenevalt kehakaalu muutumisest ja ravivastusest.
English: What measures are being taken to ensure the safe use of Omnitrope?
Estonian: Mis meetmeid võetakse, et tagada Omnitrope kasutamise ohutus?
English: This means that Omnitrope is highly similar to a biological medicine (the ‘reference medicine') that is already authorised in the EU.
Estonian: See tähendab, et Omnitrope sarnaneb bioloogilise ravimiga (võrdlusravimiga), millel juba on Euroopa Liidus müügiluba.
English: Other information about Omnitrope
Estonian: Muu teave Omnitrope kohta
English: Omnitrope must not be used if the patient has an active tumour or an acute life-threatening illness.
Estonian: Omnitropet ei tohi kasutada, kui patsiendil on aktiivne kasvaja või äge eluohtlik haigus.
English: • are short because they have long-term kidney disease or a genetic disorder called Turner syndrome;
Estonian: • kes on lühikest kasvu kroonilise neerupuudulikkuse või geneetilise häire Turneri sündroomi tõttu;
English: Omnitrope was compared with Genotropin in 89 children with a lack of growth hormone who had not been treated before.
Estonian: Omnitropet võrreldi Genotropiniga 89 lapsel, kellel oli kasvuhormooni puudulikkus ja keda ei olnud varem ravitud.
English: Why is Omnitrope approved?
Estonian: Miks Omnitrope heaks kiideti?
English: The European Medicines Agency considered that, in accordance with EU requirements for biosimilar medicines, Omnitrope has been shown to have a comparable quality, safety and effectiveness to Genotropin.
Estonian: Euroopa Ravimiamet otsustas, et vastavalt Euroopa Liidu nõuetele bioloogiliselt sarnaste ravimite kohta on tõendatud Omnitrope võrreldav kvaliteedi-, ohutus- ja efektiivsusprofiil ravimi Genotropin profiiliga.
English: As with all protein medicines, some patients may develop antibodies (proteins that are produced in response to Omnitrope).
Estonian: Nagu kõikide valguliste ravimite kasutamisel, võivad mõnel patsiendil tekkida antikehad (valgud, mis tekivad organismis reaktsioonina Omnitropele).
English: It is given by injection under the skin, once a day.
Estonian: Seda manustatakse nahaaluse süstina üks kord ööpäevas.
English: In adults, side effects related to fluid retention, such as peripheral oedema (swelling, especially of the ankles and feet), paraesthesia (numbness or tingling), joint and muscle pain, and stiffness of the limbs are common (may affect between 1 and 10 patients in 100).
Estonian: Täiskasvanutel on sagedamad kõrvalnähud (võivad esineda 1 kuni 10 patsiendil 100st) seotud vedelikupeetusega, näiteks perifeerne turse (eriti pahkluudel ja jalalabadel), paresteesia (tuimus või kirvendus), liigese- ja lihasevalu ning jäsemete jäikus.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Omnitrope have been included in the summary of product characteristics and the package leaflet.
Estonian: Omnitrope ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The doctor calculates the dose for each patient individually according to the body weight and the condition being treated.
Estonian: Arst arvutab iga patsiendi annuse eraldi, olenevalt patsiendi kehakaalust ja ravitavast seisundist.
English: It is not intended to provide practical advice on how to use Omnitrope.
Estonian: Hindamisaruandes ei anta Omnitrope kasutamise praktilisi nõuandeid.
English: Results showed that, after treatment for 9 months, Omnitrope was as effective as Genotropin in improving growth.
Estonian: Tulemustest nähtus, et pärast 9 ravikuud oli Omnitrope kasvu soodustamisel sama efektiivne kui Genotropin.
English: • are short and were born small for their gestational age, and have not caught up by the age of
Estonian: • kes on lühikesed ja kes sündisid enneaegsete lastena ning ei ole saavutanud eakohast kasvu nelja või enama aasta jooksul;
English: Therefore, the Agency's view was that, as for Genotropin, the benefit outweighs the identified risk and it recommended that Omnitrope be given marketing authorisation.
Estonian: Seetõttu arvas Euroopa Ravimiamet, et nagu ka Genotropini korral, ületab Omnitrope kasulikkus sellega kaasnevad riskid, ja soovitas ravimi Omnitrope müügiloa.
English: Somatropin is produced by a method known as ‘recombinant DNA technology': the hormone is made by bacteria into which a gene (DNA) has been introduced that makes them able to produce somatropin.
Estonian: Somatropiini valmistatakse rekombinant-DNA-tehnika abil: hormooni toodavad bakterid, millele on lisatud somatropiini teket võimaldav geen (DNA).
English: The active substance in Omnitrope, somatropin, is identical to the human growth hormone, which it replaces.
Estonian: Omnitrope toimeaine somatropiin on identne inimese kasvuhormooniga, mida see asendab.
English: This is a summary of the European public assessment report (EPAR) for Omnitrope.
Estonian: See on ravimi Omnitrope Euroopa avaliku hindamisaruande kokkuvõte.
English: For more information about treatment with Omnitrope, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Omnitropega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: What are the risks associated with Omnitrope?
Estonian: Mis riskid Omnitropega kaasnevad?
English: Omnitrope is also used as replacement therapy in adult patients with pronounced growth hormone deficiency.
Estonian: Omnitropet kasutatakse ka asendusravina kasvuhormooni väljendunud puudulikkuse raviks täiskasvanutel.
English: For practical information about using Omnitrope, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Omnitrope kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Omnitrope is given to improve their growth and body composition (by reducing fat and improving muscle mass).
Estonian: Omnitropet manustakse kasvamise soodustamiseks ja kehaehituse parandamiseks (ravimi toimel väheneb rasvkoe hulk ja suureneb lihasemass).
English: The Omnitrope cartridges should only be used with the special Omnitrope injection device.
Estonian: Omnitrope kolbampulle tohib kasutada ainult koos spetsiaalse Omnitrope süsteseadmega.
English: Omnitrope contains the active substance somatropin and is a ‘biosimilar' medicine.
Estonian: Omnitrope sisaldab toimeainena somatropiini ja on bioloogiliselt sarnane ravim.
English: Omnitrope is a medicine used to treat children who:
Estonian: Omnitrope on ravim, mida kasutatakse selliste laste raviks,
English: How is Omnitrope used?
Estonian: Kuidas Omnitropet kasutatakse?
English: The reference medicine for Omnitrope is Genotropin.
Estonian: Omnitrope võrdlusravim on Genotropin.
English: Omnitrope was studied to show that it is comparable to the reference medicine, Genotropin.
Estonian: Omnitrope uuringute eesmärk oli tõendada selle võrreldavust võrdlusravimiga Genotropin.
English: For the full list of side effects of Omnitrope, see the package leaflet.
Estonian: Omitrope kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What benefits of Omnitrope have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Omnitrope kasulikkus?
English: Omnitrope can only be obtained with a prescription and treatment should be started and monitored by a doctor experienced in the management of patients with growth disorders.
Estonian: Ravi sellega peab alustama ja jälgima kasvuhäiretega patsientide ravis kogenud arst.
English: The patient or caregiver can inject Omnitrope, after being trained by a doctor or a nurse.
Estonian: Kui patsient või tema hooldaja on saanud arstilt või õelt asjakohase väljaõppe, tohivad nad süstida Omnitropet ise.
English: The medicine is available as a powder and solvent, which are made up into a solution for injection, or as a ready-to-use solution in a cartridge.
Estonian: Ravimit turustatakse süstelahuse pulbri ja lahustina või kolbampullis valmis süstelahusena.
English: How does Omnitrope work?
Estonian: Kuidas Omnitrope toimib?
English: Howeve,r these antibodies do not have an effect on how well Omnitrope works.
Estonian: Need antikehad aga ei vähenda Omitrope toimet.
English: Growth hormone is released by the pituitary gland (a gland at the base of the brain).
Estonian: Kasvuhormoon on aine, mida eritab ajuripats (ajupõhimikul asuv nääre).
English: LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES
Estonian: RAVIMI NIMETUSTE, RAVIMVORMIDE, TUGEVUSTE, MANUSTAMISVIISIDE, MÜÜGILOA HOIDJATE LOETELU LIIKMESRIIKIDES
English: 100mg/cap Capsule, soft
Estonian: 100mg/cap Pehmekapsel
English: Belgium N.V. Novartis Pharma S.A. Medialaan 40,
Estonian: Novartis Pharma S.A. Medialaan 40, B-1800 Vilvoorde Belgium
English: 25mg/cap Capsule, soft
Estonian: 25mg/cap Pehmekapsel
English: 50mg/cap Capsule, soft
Estonian: 50mg/cap Pehmekapsel
English: The United Kingdom is the reference Member State and Germany and the Netherlands are concerned Member States.
Estonian: Viiteliikmesriik on Ühendkuningriik ja asjaomased liikmesriigid on Saksamaa ja Madalmaad.
English: The opinion was converted into a Decision by the European Commission on 21 March 2014.
Estonian: Arvamus kinnitati Euroopa Komisjoni otsusena 21. märtsil 2014.
English: EMA/128538/2014 Veterinary Medicines
Estonian: EMA/128538/2014 Veterinaarravimid
English: International non-proprietary name (INN): eprinomectin
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): eprinomektiin
English: Written explanations were provided by the applicant on 19 November
Estonian: Taotleja esitas kirjalikud selgitused 19. novembril 2013.
English: The Committee appointed C. Ibrahim as rapporteur and H. Jukes as co-rapporteur.
Estonian: Komitee määras hindajaks C. Ibrahimi ja kaashindajaks H. Jukes'i.
English: The decentralised procedure started on 21 February 2012.
Estonian: Detsentraliseeritud menetlus algas 21. veebruaril 2012.
English: Potential serious risks were identified during the decentralised procedure by Germany regarding the environmental safety of the product.
Estonian: Detsentraliseeritud menetluse käigus tuvastas Saksamaa võimalikud suured riskid seoses ravimi keskkonnaohutusega.
English: The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the summary of product characteristics and package leaflet in Annex III.
Estonian: Asjakohased raviminimetused on I lisas, teaduslikud järeldused on II lisas ning ravimi omaduste kokkuvõte ja pakendi infoleht on III lisas.
English: Norbonex 5 mg/ml Pour-On Solution for Beef and Dairy Cattle contains eprinomectin as an active substance and is intended for use in cattle as a topical application for the treatment and control of infections from gastrointestinal roundworms (adults and fourth stage larvae), lungworms (adults and fourth stage larvae), warbles (parasitic stages), mange mites, lice and horn flies.
Estonian: Liha- ja piimaveiste 5 mg/ml kriipsulahus Norbonex sisaldab toimeainena eprinomektiini ja on ette nähtud paikseks kasutamiseks gastrointestinaalsete ümarusside (täiskasvanud ja neljanda staadiumi vastsed), kopsuusside (täiskasvanud ja neljanda staadiumi vastsed), veiste kiinide (parasitaarsed staadiumid), sügelislestade, täide ja pistekärbeste tekitatud infektsioonide ravimiseks ja tõrjeks veistel.
English: Therefore, the Committee adopted by consensus a positive opinion on 15 January 2014 recommending the granting of the marketing authorisations for Norbonex 5 mg/ml Pour-On Solution for Beef and Dairy Cattle with amendment to the summary of product characteristics and package leaflet of the reference Member State.
Estonian: Seetõttu võttis komitee 15. jaanuaril 2014 vastu üksmeelse positiivse arvamuse ja soovitas anda Norbonexi (liha- ja piimaveiste 5 mg/ml kriipsulahuse) müügiloa, kui viiteliikmesriigis muudetakse ravimi omaduste kokkuvõtet ja pakendi infolehte.
English: On day 210, these issues remained unsolved and therefore a referral under Article 33(1) of Directive 2001/82/EC to the Coordination group for Mutual recognition and Decentralised procedures (veterinary) (CMD(v)) was started on 18 February 2013.
Estonian: 210. päeval olid need probleemid veel lahendamata ja sellepärast esitati 18. veebruaril 2013 veterinaarravimite vastastikuse tunnustamise ja detsentraliseeritud menetluste kooskõlastusrühmale direktiivi 2001/82/EÜ artikli 33 lõike 1 kohane esildis.
English: This is a ‘hybrid' application according to Article 13(3) of Directive 2001/82/EC, as amended, referring to the reference product Eprinex PourOn Solution for Beef and Dairy Cattle.
Estonian: See on muudetud direktiivi 2001/82/EÜ artikli 13 lõike 3 kohane hübriidtaotlus, milles viidatakse võrdlusravimile Eprinex (liha- ja piimaveiste kriipsulahus).
English: The applicant, Norbrook Laboratories Ltd, submitted an application for a decentralised procedure for Norbonex 5 mg/ml Pour-On Solution for Beef and Dairy Cattle.
Estonian: Taotleja Norbrook Laboratories Ltd esitas liha- ja piimaveiste 5 mg/ml kriipsulahuse Norbonex detsentraliseeritud menetluse taotluse.
English: Day 60 of the CMD(v) procedure was on 18 April 2013, and since the Member States concerned failed to reach an agreement regarding the product the procedure was referred to the CVMP.
Estonian: Veterinaarravimite vastastikuse tunnustamise ja detsentraliseeritud menetluste kooskõlastusrühma menetluse 60. päev oli 18. aprill 2013 ja et asjaomased liikmesriigid ei olnud jõudnud selleks ajaks ravimi suhtes kokkuleppele, suunati menetlus edasi veterinaarravimite komiteele.
English: Based on the evaluation of the currently available data, the CVMP considered that the benefit-risk profile of Norbonex 5 mg/ml Pour-On Solution for Beef and Dairy Cattle is positive.
Estonian: Olemasolevaid andmeid hinnates otsustas veterinaarravimite komitee, et Norbonexi (liha- ja piimaveiste 5 mg/ml kriipsulahuse) kasulikkuse ja riski profiil on positiivne.
English: Opinion following an Article 33(4)1 referral for Norbonex 5 mg/ml Pour-On Solution for Beef and Dairy Cattle
Estonian: Arvamus pärast artikli 33 lõike 41 kohast esildist Liha- ja piimaveiste 5 mg/ml kriipsulahus Norbonex
English: Opinion following an Article 33(4)0F referral for Norbonex 5 mg/ml Pour-On Solution for Beef and Dairy Cattle
Estonian: Arvamus pärast artikli 33 lõike 40F kohast esildist Liha- ja piimaveiste 5 mg/ml kriipsulahus Norbonex EMA/128538/2014
English: On 26 April 2013, the reference Member State, the United Kingdom, notified the Agency that the CMD(v) had failed to reach an agreement regarding the product and referred the matter to the CVMP pursuant to Article 33(4) of Directive 2001/82/EC.
Estonian: 26. aprillil 2013 teatas viiteliikmesriik Ühendkuningriik Euroopa Ravimiametile, et veterinaarravimite vastastikuse tunnustamise ja detsentraliseeritud menetluste kooskõlastusrühm ei jõudnud ravimi
English: 1.3 - Not Reached
Estonian: 1,3 - Ei ole saavutatud
English: For the attention of dog owner
Estonian: Tähelepanuks koera omanikule
English: Reversal should occur rapidly within 1-2 minutes.
Estonian: Antagonism peaks toimuma kiiresti, 1-2 minuti jooksul.
English: 3.0 to 4.2 4.3 to 6.1 6.2 to 8.0 8.1 to 9.9 10.0 to 11.7 11.8 to 13.6 13.7 to 15.5 15.6 to 17.4 17.5 to 19.3 19.4 to 21.2 21.3 to 23.1 23.2 to 25.0 25.1 to 26.9 27.0 to 28.8 28.9 to 30.6 30.7 to 32.5 32.6 to 34.4 34.5 to 36.3 36.4 to 38.2 38.3 to 40.1 40.2 to 42.0 42.1 to 43.9 44.0 to 45.8 45.9 to 47.7 47.8 to 49.6 49.7 to 51.4 51.5 to 53.3 53.4 to 55.2 55.3 to 57.0
Estonian: 4,3 kuni 6,1 6,2 kuni 8,0 8,1 kuni 9,9 10,0 kuni 11,7 11,8 kuni 13,6 13,7 kuni 15,5 15,6 kuni 17,4 17,5 kuni 19,3 19,4 kuni 21,2 21,3 kuni 23,1 23,2 kuni 25,0 25,1 kuni 26,9 27,0 kuni 28,8 28,9 kuni 30,6 30,7 kuni 32,5 32,6 kuni 34,4 34,5 kuni 36,3 36,4 kuni 38,2 38,3 kuni 40,1 40,2 kuni 42,0 42,1 kuni 43,9 44,0 kuni 45,8 45,9 kuni 47,7 47,8 kuni 49,6 49,7 kuni 51,4 51,5 kuni 53,3 53,4 kuni 55,2 55,3 kuni 57,0
English: This dog was treated on: Date
Estonian: Seda koera raviti: Kuupäev
English: Your veterinarian can best describe these for you.
Estonian: Teie veterinaararst saab neid teie jaoks kõige paremini selgitada.
English: MARKETING AUTHORISATION NUMBER(S) EU/2/11/127/001
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/2/11/127/001
English: The application site should be clean and free of any surface matter.
Estonian: Manustamispiirkond peaks olema puhas ja vaba mistahes pinnaainest.
English: It can cause:
Estonian: Recuvyra võib põhjustada:
English: The systemic bioavailability of the veterinary medicinal product is approximately 40%.
Estonian: Veterinaarravimi süsteemne biosaadavus on umbes 40%.
English: Your veterinarian will ensure the product is stored correctly and safely for up to 3 years, but the contents of a bottle should be used within 30 days of the first dose being withdrawn.
Estonian: Veterinaararst tagab, et preparaat säilitatakse korrektselt ja ohutult kuni 3 aastat, kuid pudeli sisu tuleks kasutada 30 päeva jooksul pärast esimese annuse väljatõmbamist.
English: Keep this package leaflet in a safe place.
Estonian: Hoidke seda pakendi infolehte turvalises kohas.
English: As a precaution, RECUVYRA should not be administered by pregnant women.
Estonian: Ettevaatusabinõuna ei tohiks Recuvyra't manustada rasedad naised.